ACE inhibitors for secondary prevention after myocardial infarction in patients with left ventricular dysfunction
Sübutlu məlumatların xülasələri
29.12.2015 • Sonuncu dəyişiklik 29.12.2015
ACE inhibitors reduce mortality, hospitalisation for congestive heart failure, and recurrent non-fatal myocardial infarction in people with left ventricular dysfunction after myocardial infarction.
A topic in Clinical Evidence summarizes the evidence on ACE inhibitors in patients with myocardial infarction and left ventricular dysfunction. A systematic review of 3 RCTs (5 966 people). ACE inhibitors significantly reduced mortality (OR 0.74, 95% CI 0.66 to 0.83, NNT 17 during 2 years), hospitalisation for congestive heart failure (OR 0.73, 95% CI 0.63 to 0.85, NNT 28) and recurrent non-fatal myocardial infarction (OR 0.80, 95% CI 0.69 to 0.94, NNT 43).
The following decision support rules contain links to this evidence summary:
- ACEI/ARB and beta-blockers for patients with congestive heart failure
Ədəbiyyat
- Sudlow C, Lonn E, Pignone M, Ness A, Rihal C. Secondary prevention of ischaemic cardiac events. Clin Evid 2002 Jun;(7):124-60.